Drugs / GIM122
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06028074 | Dec 2023 → Sep 2026 overdue | high grade malignant neoplasm | Georgiamune Inc | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GIM122 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06028074 ↗ |
| Modality | Monoclonal antibody | “GIM-122 is a first-in-class, humanized immunoglobulin G1 kappa dual functioning monoclonal antibody (DFA).” NCT06028074 ↗ |
| Route | Intravenous | “intravenous (IV) administration of GIM-122” NCT06028074 ↗ |